Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing innovative products to treat selected gastrointestinal disorders and improve endoscopy quality measures, such as by aiding the detection of colonic lesions. Their portfolio includes treatments for conditions like Ulcerative Colitis, Irritable Bowel Syndrome with Diarrhea (IBS-D), and products used in colonoscopy procedures. Cosmo aims to address unmet medical needs in gastroenterology and endoscopy through targeted therapies and novel medical devices.
Serves as the global corporate headquarters, overseeing strategic direction, financial management, research and development coordination, and administrative functions for Cosmo Pharmaceuticals' worldwide operations.
Modern office facility located in the Riverside Business Park, designed to support a collaborative and efficient work environment for its corporate and R&D leadership teams.
A dynamic, science-driven, and patient-focused work culture. Emphasizes innovation, ethical practices, teamwork, and continuous improvement in the development of pharmaceutical solutions.
The Dublin headquarters is strategically important for Cosmo's global operations, leveraging Ireland's established position as a European hub for the pharmaceutical and life sciences industry, offering benefits in terms of talent pool and business environment.
Cosmo Pharmaceuticals has a focused global presence with key operational centers in Europe and North America. Its headquarters are in Dublin, Ireland, with major manufacturing and R&D facilities in Lainate, Italy, and U.S. commercial operations based in San Diego, California. Cosmo's products are marketed and distributed in over 40 countries worldwide, either directly or through a network of licensing and distribution partners, enabling access to its specialized gastroenterology and endoscopy solutions across key international markets.
Riverside II, Mulhuddart
Dublin
Dublin 15
Ireland
Address: Via C. Colombo 1, 20045 Lainate (MI), Italy
Serves as a key European manufacturing and R&D hub, supporting the development and supply of products for both European and international markets, benefiting from Italy's robust pharmaceutical sector.
Address: 9171 Towne Centre Drive, Suite 455, San Diego, CA 92122, USA
Focuses on the strategic U.S. pharmaceutical market, driving commercialization efforts, engaging with healthcare professionals, and navigating the regulatory landscape specific to the United States.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cosmo' leadership includes:
Cosmo has been backed by several prominent investors over the years, including:
Over the last 12 months, Cosmo Pharmaceuticals strengthened its executive leadership, notably with the appointment of Giovanni Di Napoli to head its commercial operations for GI and Endoscopy, indicating a focus on enhancing its market presence and commercial strategy.
Discover the tools Cosmo uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cosmo Pharmaceuticals likely utilizes standard corporate email formats. Based on common patterns for companies of its size and structure, a primary format is often [first_initial][last]@cosmopharma.com or [first].[last]@cosmopharma.com. For example, an employee named Jane Doe might have an email address like jdoe@cosmopharma.com.
[first_initial][last]@cosmopharma.com
Format
jdoe@cosmopharma.com
Example
75%
Success rate
Cosmo Pharmaceuticals N.V. Press Release • April 25, 2024
Cosmo Pharmaceuticals announced that the Phase III pivotal study results for its investigational drug Clascoterone solution for the treatment of Androgenetic Alopecia (AGA) were published in the peer-reviewed Journal of the American Academy of Dermatology (JAAD). This publication highlights the efficacy and safety data, representing a key milestone for the product's development....more
Cosmo Pharmaceuticals N.V. Press Release • February 29, 2024
Cosmo Pharmaceuticals released its full-year financial results for 2023, reporting total revenues of €101.8 million and an operating profit. The company highlighted strong performance from key products like Byfavo® and Winlevi® and provided a positive outlook for 2024, anticipating continued revenue growth and advancements in its clinical pipeline....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cosmo, are just a search away.